Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.

Also called NCT03815292

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 276 participants (enrolled count) (from the registry)
Sponsor
Materia Medica Holding (from the registry)
Registry
  • NCT NCT03815292
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03815292. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-19 (actual); primary completion 2020-01-27 (actual). Results posted on 2021-02-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
Condition
Mild Cognitive Impairment
Intervention (Drug)
MMH-MAP
Intervention (Drug)
Placebo
Lead sponsor
Materia Medica Holding (class: industry)

Record details

Record id
cardio:ct-nct03815292
Content hash
a9f3bca3d8b4245793c213f39ef6d8a8f76f1176d2bfed2661e33e41acb83aa5